Cognitive Function and Prevalence of Amyloid Marker in Frail Older Adults

The COGFRAIL study is a monocentric study integrating the longitudinal follow-up of 345 individuals referred to the Toulouse Frailty Clinic during 2 years. The procedure consists in neuroimaging to diagnose the presence of amyloid plaques in the brains and permit earlier detection of Alzheimer's disease.

• Visits will be scheduled at baseline, 1 and 2 years for a full neuropsychological, functional and physical evaluation.
• At 6 and 18 months patients will be seen in consultation by a Geriatrician and research assistant for a medical check.
• PET-Scan will be scheduled in the 2 months following inclusion for amyloid measurements. The MRI will be proposed, depending on the clinical relevance
• A blood sample for biobank will be taken at visit 2 and at the end of the study

Extension study (CogFrail-Plus):

The extension study will integrate an additional 2 years follow-up of the

COGFRAIL study participants, following the initial 2 years period of the study:

• 2 Visits will be scheduled at 36 and 48 months for a full neuropsychological, functional and physical evaluation
• At 30 and 42 months patients will be seen in consultation by a Geriatrician and research assistant for a medical check
• A blood sample will be taken at 36 and 48 months.

Inclusion criteria

• Female and male individuals referred to the Toulouse Frailty Clinic with an objective memory impairment (CDR=0.5 or CDR=1)
• Age ≥ 70 years
• At least 1 Fried-criterion
• Informed consent signed by the patient
• Having an informant accompanying or available by phone
• Individuals affiliated to a healthcare scheme.
• - Willing to be informed in case of a new pathology discovered through medical examination

Extension study (Cog-Frail Plus):

• COGFRAIL study participants still included in the study and completing their last visit (M 24)
• Having a family member or legal representant to sign the consent form if MMSE score <20 at the last visit (M24)

Exclusion criteria

• Individuals presenting severe visual or auditory difficulties which may interfere with the completion of neuropsychological and functional assessments.
• Presence of any pathology or severe clinical or psychological condition that, according to the investigator, might interfere with study results or may expose the participants to additional risks.
• Individuals who are robust according to the Fried criteria (0 criteria)
• Individuals who are dependent (Activities of Daily Living (ADL) <4)
• Individuals who have a major deterioration in global cognitive function (Mini Mental State Examination (MMSE) <20)
• Subjects deprived of their liberty by administrative or judicial decision, or under guardianship or admitted to a healthcare or social institution (subjects in non-assisted living facilities could be recruited);

Exclusion criteria

for MRI scanning :

• Claustrophobia
• Trauma or surgery which may have left ferromagnetic material in the body, including pacemakers
• History of neurosurgery or aneurism

Extension study (Cog-Frail Plus):

• Presence of any severe pathology that, according to the investigator, might interfere with study results or may expose the participants to additional risks.
• Subjects deprived of their liberty by administrative or judicial decision, or under guardianship